BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)
NCT07009899
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
34
Enrollment
OTHER
Sponsor class
Conditions
Multiple Myeloma
Interventions
DRUG:
Linvoseltamab
Sponsor
Medical College of Wisconsin